Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Gali Maor"'
Autor:
Or Cabasso, Sumit Paul, Gali Maor, Metsada Pasmanik-Chor, Wouter Kallemeijn, Johannes Aerts, Mia Horowitz
Publikováno v:
Cells, Vol 10, Iss 3, p 630 (2021)
Human GBA1 encodes lysosomal acid β-glucocerebrosidase (GCase), which hydrolyzes cleavage of the beta-glucosidic linkage of glucosylceramide (GlcCer). Mutations in this gene lead to reduced GCase activity, accumulation of glucosylceramide and glucos
Externí odkaz:
https://doaj.org/article/1a3b960c9e94479e8bff3c7edfa4213b
Autor:
Gali Maor, Sumit Paul, Johannes M. F. G. Aerts, Or Cabasso, Mia Horowitz, Wouter W. Kallemeijn, Metsada Pasmanik-Chor
Publikováno v:
Cells, Vol 10, Iss 630, p 630 (2021)
Cells, 10(3). MDPI} {AG
Cells
Volume 10
Issue 3
Cells, 10(3). MDPI} {AG
Cells
Volume 10
Issue 3
Human GBA1 encodes lysosomal acid β-glucocerebrosidase (GCase), which hydrolyzes cleavage of the beta-glucosidic linkage of glucosylceramide (GlcCer). Mutations in this gene lead to reduced GCase activity, accumulation of glucosylceramide and glucos
Publikováno v:
International Journal of Molecular Sciences
Volume 21
Issue 19
International Journal of Molecular Sciences, Vol 21, Iss 7397, p 7397 (2020)
Volume 21
Issue 19
International Journal of Molecular Sciences, Vol 21, Iss 7397, p 7397 (2020)
Fabry disease, an X-linked recessive lysosomal disease, results from mutations in the GLA gene encoding lysosomal &alpha
galactosidase A (&alpha
Gal A). Due to these mutations, there is accumulation of globotriaosylceramide (GL-3) in plasma
galactosidase A (&alpha
Gal A). Due to these mutations, there is accumulation of globotriaosylceramide (GL-3) in plasma
Publikováno v:
Blood Cells, Molecules, and Diseases. 68:21-29
Chronic presence of mutant, misfolded proteins in the endoplasmic reticulum (ER) initiates ER stress and induces the Unfolded Protein Response (UPR).In Gaucher disease (GD), resulting from mutations in the GBA1 gene, encoding lysosomal acid β-glucoc
Autor:
Orly Dorot, Or Cabasso, Johannes M. F. G. Aerts, Gali Maor, Metsada Pasmanik-Chor, Mina Mirzaian, Sumit Paul, Maria J. Ferraz, Mia Horowitz, Olga Krivoruk
Publikováno v:
Journal of Clinical Medicine, Vol 8, Iss 9, p 1420 (2019)
Journal of Clinical Medicine
Journal of Clinical Medicine, 8(9), 1420. MDPI
Journal of Clinical Medicine; Volume 8; Issue 9; Pages: 1420
Journal of Clinical Medicine
Journal of Clinical Medicine, 8(9), 1420. MDPI
Journal of Clinical Medicine; Volume 8; Issue 9; Pages: 1420
Gaucher disease (GD) results from mutations in the GBA1 gene, which encodes lysosomal glucocerebrosidase (GCase). The large number of mutations known to date in the gene lead to a heterogeneous disorder, which is divided into a non-neuronopathic, typ
Publikováno v:
Human molecular genetics. 28(11)
Gaucher disease (GD) patients and carriers of GD mutations have a higher propensity to develop Parkinson's disease (PD) in comparison to the non-GD population. This implies that mutant GBA1 allele is a predisposing factor for the development of PD. O
Publikováno v:
Molecular Genetics and Metabolism. 126:S35
Publikováno v:
Gaucher Disease: Basic and Clinical Perspectives. :140-157
Publikováno v:
Blood Cells, Molecules & Diseases
Gaucher disease (GD) is characterized by accumulation of glucosylceramide in lysosomes due to mutations in the GBA1 gene encoding the lysosomal hydrolase β-glucocerebrosidase (GCase). The disease has a broad spectrum of phenotypes, which were divide